Bio Green Med Solution, Inc. annual report, FY2018

Filing and reporting period

Entity mismatch: The request identifies Bio Green Med Solution, Inc., but the supplied filing is Cyclacel Pharmaceuticals, Inc.’s Form 10-K. This summary covers Cyclacel’s fiscal year ended December 31, 2018, not a standalone 2018 fourth-quarter report. Cyclacel is a clinical-stage biopharmaceutical company focused on oncology and hematology; it reported no approved products in development.

Financial performance and liquidity

2018 revenue was a milestone payment under the ManRos collaboration. Research and development expense was $4.327 million, up 2%; higher CYC065 spending was largely offset by lower SEAMLESS-related sapacitabine costs. General and administrative expense was $5.371 million, up 2%. The company recorded $1.337 million in UK R&D tax credits and $0.923 million in net other income. No gross margin measure is presented, and the filing does not report material interest-bearing debt. Total liabilities were $4.551 million; these include current liabilities and other liabilities, not a stated debt balance.

Cash declined by $6.406 million during 2018. Financing provided $0.429 million, including approximately $0.630 million net proceeds from an at-the-market stock sale, partly offset by $0.201 million of preferred dividends. The company reported an accumulated deficit of $349.8 million. It estimated that available funds and expected receipts would support planned operations through at least the second quarter of 2020; continued operations beyond then depend on raising additional capital or other funding measures.

Material changes and operating developments

• The SEAMLESS Phase 3 trial of sapacitabine in elderly AML patients did not meet its primary endpoint of statistically significant improvement in overall survival. A higher complete-remission rate was observed, and exploratory analyses indicated a possible benefit trend in the subgroup with low baseline white blood cell counts. The company continued regulatory discussions but disclosed no assured approval pathway.
• CYC065 became the larger R&D focus: spending rose from $1.057 million to $2.522 million as clinical evaluation progressed. Its Phase 1 study established a recommended Phase 2 dose; the filing reports pharmacodynamic activity and some prolonged stable disease, not proof of efficacy.
• In October 2018, Cyclacel entered a three-year MD Anderson collaboration covering four planned studies and up to 170 patients. MD Anderson assumes patient costs; Cyclacel supplies study drugs and limited support and may owe payments upon first commercial sale in specified indications.
• In 2018, the company sold 500,000 shares through its at-the-market agreement for approximately $0.7 million gross. After year-end it sold another 4.7 million shares for approximately $4.3 million gross, exhausting the agreement’s $5 million maximum offering amount.

Outlook, risks and unusual items

Management expected 2019 R&D expense to increase as CYC065 development advanced and general and administrative expense to decrease. It anticipated higher UK R&D tax credits, subject to qualifying expenditures. These are expectations, not guaranteed outcomes. The filing states that management did not identify conditions raising substantial doubt about the company’s ability to continue as a going concern for at least one year from issuance, while also warning that funding beyond the second quarter of 2020 would be needed.

• Clinical and regulatory risk: Drug candidates remain investigational; trial results may be inconclusive or unsafe, and regulatory authorities may reject or require further evidence. SEAMLESS missed its primary endpoint, and subgroup findings are exploratory.
• Financing and dilution: Ongoing losses and clinical costs require additional funding; equity financing may dilute shareholders. As of December 31, 2018, 7.49 million warrants were outstanding with a $2.00 exercise price, in addition to preferred stock and options.
• Listing risk: Nasdaq notified Cyclacel in January 2019 that it had not regained compliance with the $1.00 minimum bid-price requirement and gave it until July 7, 2019 to do so, subject to possible extension.
• Preferred-stock claims: The 6% convertible exchangeable preferred stock carried $0.7 million of accrued unpaid dividends at year-end and requires quarterly dividends when declared. Its liquidation preference was approximately $4.0 million.
• Foreign exchange: A $9.336 million unrealized loss on long-term intercompany loans was recorded in other comprehensive loss in 2018; it was not part of net loss. Changes in exchange rates also affected reported results.
• Other unusual items: Other income included $0.682 million of royalties under a legacy asset-purchase agreement, which Cyclacel said it could not forecast. The company expects to recognize about $1.6 million in lease liability and a corresponding right-of-use asset upon adoption of the new lease standard.

Most important facts for investors to verify

• Confirm the issuer: the supplied 10-K is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
• Review the full audited financial statements and notes, especially cash runway assumptions, subsequent share sales, preferred dividends, and dilution from warrants and other securities.
• Track regulatory feedback and any concrete next steps for sapacitabine after SEAMLESS failed its primary endpoint; distinguish exploratory subgroup results from confirmatory evidence.
• Check the status, enrollment, safety findings and results of CYC065 and combination trials, including the MD Anderson studies.
• Verify the company’s Nasdaq bid-price compliance and financing needs against the latest filings, since the stated runway is based on management estimates.